Rock Springs Capital ASND Position
Active11-Fund ConvergenceRock Springs Capital trimmed their position in Ascendis Pharma A/S (ASND) in Q4 2025, holding $43.4M worth of shares across 203,500 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ASND is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Navepegritide in 259 days (Dec 31, 2026), making the timing of Rock Springs's position particularly relevant.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Full company profile →Short Interest
7.5%
5.2 days to cover
Rock Springs Capital ASND Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 203,500 | -11,000 | $43.4M |
| Q3 2025 | Decreased | 214,500 | -2,500 | $42.6M |
| Q2 2025 | Increased | 217,000 | +1,000 | $37.5M |
| Q1 2025 | Decreased | 216,000 | -89,000 | $33.7M |
| Q4 2024 | Decreased | 305,000 | -20,000 | $42.0M |
| Q3 2024 | Increased | 325,000 | +35,000 | $48.5M |
| Q2 2024 | Held | 290,000 | — | $39.5M |
| Q1 2024 | Held | 290,000 | — | $43.8M |
| Q4 2023 | Decreased | 290,000 | -135,500 | $36.5M |
| Q3 2023 | Held | 425,500 | — | $39.8M |
| Q2 2023 | Held | 425,500 | — | $38.0M |
| Q1 2023 | New | 425,500 | +425,500 | $45.6M |
Frequently Asked Questions
Does Rock Springs Capital own ASND?
Yes. As of Q4 2025, Rock Springs Capital holds 203,500 shares of Ascendis Pharma A/S (ASND) valued at $43.4M. This data comes from their SEC 13F filing.
How many hedge funds own ASND?
11 specialist biotech hedge funds currently hold ASND, including RA Capital Management, Avoro Capital Advisors, Perceptive Advisors and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy ASND?
Rock Springs Capital's position in ASND was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's ASND position increasing or decreasing?
Rock Springs Capital trimmed their ASND position in the most recent quarter, reducing by 11,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ASNDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →